Lakefront Biotherapeutics NV

What they do

The company operates as a biopharmaceutical developer with a pipeline including a TYK2 program (GLPG3667), a SIK3 inhibitor program, and CAR T programs in oncology. It also has a drug discovery platform and collaborates with Gilead on filgotinib and ziritaxestat. The company is transitioning its commercial operations, having classified several European subsidiaries as discontinued operations in 2025.

Revenue drivers

• Jyseleca (filgotinib) royalties — Royalties from Gilead on sales of Jyseleca, a selective JAK1 inhibitor for rheumatoid arthritis and ulcerative colitis, represent a continuing revenue stream though no specific amount was provided.
• Collaborative agreements — Revenue from collaboration agreements with Gilead, including the filgotinib performance obligation and the ziritaxestat collaboration, contribute to periodic milestone or service-based payments.
• Drug discovery platform — A collaboration agreement with Gilead for a drug discovery platform provides upfront and ongoing payments, but the relative size was not disclosed in the excerpts.

Recent performance

For fiscal year 2025, the company reported total revenue of approximately €81.5 million, a decline from €45.5 million in 2024 and €44.8 million in 2023. R&D expenses totaled €163.2 million, up from lower prior-year amounts, reflecting continued investment in pipeline programs. The company had cash and equivalents of €132.0 million at year-end 2025, compared to €65.9 million in 2024.

Strategy

Management is focusing on advancing its pipeline, particularly the TYK2 program (GLPG3667) and SIK3 inhibitor program, while maintaining a cell therapy presence in oncology. The company has restructured its operations, moving certain European subsidiaries to discontinued operations, and has changed its name from Galapagos to Lakefront Biotherapeutics. It continues to invest in external collaborations and outsource key R&D activities.

Risks

• Clinical development risk — Pipeline candidates such as GLPG3667 (TYK2) and the SIK3 program may fail in clinical trials, causing delays or write-offs.
• Dependence on Gilead collaboration — A significant portion of revenue and royalties depends on the Gilead agreements, which could be terminated or renegotiated.
• Cash burn and funding need — With R&D expenditures exceeding revenue, the company may require additional capital to fund operations beyond its cash balance.
• Restructuring execution — The move to discontinue European commercial operations may disrupt existing partnerships and incur unexpected costs.

Outlook

Management expects to continue advancing its clinical pipeline, with key readouts anticipated for GLPG3667 and the SIK3 program. The company is prioritizing cost efficiency and may further streamline its operations. Guidance on specific timelines or financial forecasts was not provided in the excerpts.